Sun Pharmaceutical Industries Limited — Updates, 28-03-2026: General Updates

Sun Pharma's partner Philogen released mixed clinical data. Fibromun's Phase II failed in sarcoma and glioblastoma, though a new Phase III for sarcoma is planned. Nidlegy showed strong Phase II results in skin cancers, leading to multiple new registrational studies and US melanoma regulatory alignment.